New findings presented today show that CONCERTA is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common and treatable child behavioral problem characterized by inattention, hyperactivity and impulsivity(1) that is estimated to affect about 5 million children(2) in the United States.

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., presented the data at the U.S. Psychiatric and Mental Health Congress (Poster 303: Time Course of Treatment Effect of Concerta® [OROS® Methylphenidate] in Children with ADHD).

“Untreated ADHD symptoms can present challenges throughout a child’s day, so new findings on onset and duration of effect are important to understand,” said Matthew Brams*, M.D., a practicing psychiatrist in Houston, Clinical Assistant Professor at Baylor College of Medicine and an investigator who participated in one of the studies. “There’s benefit in medication that acts quickly and lasts through the day, providing treatment coverage when a child may need it in the early morning, through the activities of the day and into the early evening hours.”

The results presented today showed significant improvements in attention with CONCERTA® versus placebo as measured by a validated, time-sensitive math test administered throughout the day.

At one hour post-dose, subjects who received CONCERTA® attempted 38 percent more math problems compared with baseline (from 75.8 problems attempted before treatment to 104.4 problems attempted after treatment), while those receiving placebo showed no change from baseline (from 80.6 problems attempted before treatment to 80 problems attempted after treatment).

The results were statistically significant throughout the study’s interim time points, from the first testing point at one hour after dosing (p<0.0001) through to the final assessment at 12.5 hours (p<0.0001). Accuracy, as measured by percentage of problems correct, was similar for both treatment groups and was consistent across the period of observation (placebo, 92.1 percent to 93.5 percent and CONCERTA®, 94.0 percent to 94.3 percent).

SOURCE McNeil Pediatrics(TM)

Tweet This Post